Day: March 5, 2025

Full year 2024 Revenue Growth of 3.4%, Net Income increased 208.6% to $19.0 million Full year 2024 Adjusted EBITDA (non-GAAP) of $82.5 million, an increase of 25.3% Full year 2024 Net Cash from Operations of $50.1 million, an increase of 87.4%; Free Cash Flow (non-GAAP) of $27.1 million, an increase of 775.9% Full year 2024 Selling, General and Administrative expenses decreased $10.4 million or 6.2% PRINCETON JUNCTION, N.J., March 05, 2025 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE), a leading “one source” multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its fourth quarter and twelve months ended December 31, 2024. Highlights of the Fourth Quarter 2024*Income from Operations of $10.5 million Net income of $5.3 million and Earnings Per Diluted...

Dallas, Texas, March 05, 2025 (GLOBE NEWSWIRE) — CompX International Inc. (NYSE American: CIX) announced today net sales of $38.4 million for the fourth quarter of 2024 compared to $43.2 million in the same period of 2023. Operating income was $4.9 million in the fourth quarter of 2024 compared to $7.4 million in the same period of 2023. Net income was $4.5 million, or $.37 per basic and diluted common share, for the fourth quarter of 2024 compared to $6.7 million, or $.54 per basic and diluted common share, in the same period of 2023. Net sales for the year ended December 31, 2024 were $145.9 million compared to $161.3 million in the previous year. Operating income was $17.0 million for the year ended December 31, 2024 compared to $25.4 million in 2023. Net income for the year ended December 31, 2024 was $16.6 million, or $1.35...

Fourth quarter comparable sales increase 5%Operating Income and EPS exceed expectationsProvides initial full year and first quarter 2025 guidance REYNOLDSBURG, Ohio, March 05, 2025 (GLOBE NEWSWIRE) — Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSCO) today reported financial results for the fourth quarter and fiscal year ended February 1, 2025. “I am pleased with the strength of our fourth quarter holiday results, which saw sales up in both our Victoria’s Secret and PINK brands and our powerhouse Beauty business. Sales increased across most major merchandise categories, in our stores and digital channels, and in both our North America and International businesses. We won in the big moments of the quarter and gained more than our fair share of the traffic in the mall and online. The teams focused on execution...

Equipment Fleet and Working Capital Management Generate Strong Fourth Quarter Cash Flows as Pressured Volumes and Gross Margins on Equipment Sales Drive Quarterly and Annual Earnings Decline Fourth Quarter Financial Highlights: (comparisons are year over year)Total revenues decreased 4.5% year over year to $498.1 million Construction and Material Handling revenues of $318.6 million and $168.6 million, respectively Product support revenues decreased 2.3% year over year with Parts sales decreasing to $67.9 million and Service revenues decreasing to $59.0 million New and used equipment sales decreased 3.7% to $287.1 million Net loss available to common stockholders of $(11.4) million compared to $(2.7) million in 2023 Basic and diluted net loss per share of $(0.34) compared to $(0.08) in 2023 Adjusted basic and diluted pre-tax net (loss)...

BERKELEY, Calif., March 05, 2025 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter and Full-Year 2024 Financial HighlightsRevenues for the three months ended December 31, 2024 were $2.3 million Operating expenses for the three months ended December 31, 2024 were $19.5 million Operating loss for the three months ended December 31, 2024 was $18.5 million Net loss for the three months ended December 31, 2024 was $153.0 million, including $135.1 million of non-cash charges for the fair value change in the earn-out and derivative warrant liabilities For the year ended December 31, 2024, revenues were $10.8 million, operating expenses...

– Implemented Cost Savings Expected to Yield Approximately $8 Million Annually – – Integrated Accretive Acquisition of a Beverage-grade Liquid CO2 Processor –– Considering Asset Sales, a Merger or Other Strategic Transactions – PEKIN, Ill., March 05, 2025 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, reported its financial results for the quarter and year ended December 31, 2024. Bryon McGregor, President and Chief Executive Officer of Alto Ingredients said, “During the fourth quarter of 2024 and the first quarter of 2025, we implemented cost saving initiatives, including cold idling our Magic Valley plant, and lowering total company headcount by 16%. We expect these staffing reductions...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin Acceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC) Reported $324.2 million in cash resources as of December 31, 2024, which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027 Will host conference call with management today at 4:30 p.m. Eastern...

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business updates. “Our objective and strategy to become a leader in in vivo gene editing accelerated in the fourth quarter after we achieved in vivo preclinical...

FY 2024 Net Income up 51% to $18.6 Million or $4.06 per share; Adjusted Net Income up 64% to $24.0 Million or $5.26 per share; Adjusted EBITDA up 61% to $39.6 Million Q4 & FY 2024 Net Sales, Gross Profit, Net Income, EPS and Adjusted EBITDA Increase to Record Levels EATONTOWN, N.J., March 05, 2025 (GLOBE NEWSWIRE) — Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Company”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, is reporting results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Summary vs. Same Year-Ago QuarterNet sales increased 51% to $161.8 million. Net income increased 33% to $7.0 million or $1.52 per diluted share. Adjusted net income (a non-GAAP financial measure defined below) increased...